A population-based study found the anti-obesity drug orlistat does not appear to raise the short-term risk of colorectal cancer, according to researchers at the University of North Carolina at Chapel Hill. They cautioned, however, that because of study limitations, the possibility that long-term use of orlistat may raise CRC risk cannot be excluded.

Related Summaries